NCT01371617View on ClinicalTrials.gov

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Primary MyelofibrosisFibrosis, Bone Marrow
Interventions
DRUG

IPI-926

Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF

Trial Locations (3)

77030

The University of Texas MD Anderson Cancer Center, Houston

85260

Arizona Mayo Clinic, Scottsdale

94025

Stanford University School of Medicine, Division of Hematology, Palo Alto

Sponsors
All Listed Sponsors
lead

Infinity Pharmaceuticals, Inc.

INDUSTRY